Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/40013
Title: Phase II, randomized, placebo-controlled study of dovitinib in combination with fulvestrant in postmenopausal patients with HR+, HER2- breast cancer that had progressed during or after prior endocrine therapy.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: Breast Cancer Res..2017 02;(19)1:18
Abstract: Overexpression of fibroblast growth factor receptor 1 (FGFR1), found in ≤8% of hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer cases, is correlated with decreased overall survival and resistance to endocrine therapy (ET). Dovitinib, a potent FGFR inhibitor, has demonstrated antitumor activity in heavily pretreated patients with FGFR pathway-amplified breast cancer.
PMID: 28183331
URI: https://hdl.handle.net/20.500.12530/40013
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:
File Description SizeFormat 
PMC5301372.pdf940.92 kBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.